This company listing is no longer active
Acerus Pharmaceuticals Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 0/6
Acerus Pharmaceuticals has a total shareholder equity of $-13.9M and total debt of $45.8M, which brings its debt-to-equity ratio to -329.8%. Its total assets and total liabilities are $47.7M and $61.6M respectively.
Wichtige Informationen
-329.8%
Verhältnis von Schulden zu Eigenkapital
US$45.82m
Verschuldung
| Zinsdeckungsgrad | n/a |
| Bargeld | US$3.02m |
| Eigenkapital | -US$13.89m |
| Gesamtverbindlichkeiten | US$61.57m |
| Gesamtvermögen | US$47.67m |
Jüngste Berichte zur Finanzlage
Keine Aktualisierungen
Recent updates
Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: ASPC.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langfristige Verbindlichkeiten: ASPC.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: ASPC.Q has negative shareholder equity, which is a more serious situation than a high debt level.
Schulden abbauen: ASPC.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilanz
Liquiditätsreserve-Analyse
Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.
Stabile Start- und Landebahn für Bargeld: ASPC.Q has less than a year of cash runway based on its current free cash flow.
Vorhersage Cash Runway: ASPC.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 45.6% each year